:
Cancer immunotherapy endeavours in harnessing delicate strength and specificity of immune system for therapy
of different malignancies including colorectal carcinoma. The recent challenge for cancer immunotherapy is to practice and
develop molecular immunology tools to create tactics that efficiently and securely boost antitumor reactions. After several
attempts of deceptive outcomes, the wave has lastly altered and immunotherapy has become a clinically confirmed treatment
for several cancers. Immunotherapeutic methods include administration of antibodies or modified proteins that either block
cellular activity or co-stimulate cells through immune control pathways, cancer vaccines, oncolytic bacteria, ex vivo
activated adoptive transfer of T cells and natural killer cells. Engineered T cells are used to produce a chimeric antigen
receptor (CAR) to treat different malignancies including colorectal carcinoma in a recent decade. Despite considerable early
clinical success, CAR-T therapies are associated with some side effects and sometimes display minimal efficacy. It gives
special emphasis on the latest clinical evidence with CAR-T technology and also other related immunotherapeutic methods
with promising performance, and highlighted how this therapy can affect therapeutic outcome and next upsurge as a key
clinical aspect of colorectal carcinoma. In this review we recapitulate the current developments produced to improve the
efficacy and specificity of CAR-T therapies in colon cancer.
Cutting Edge: Heligmosomoides polygyrus Induces TLR4 on Murine Mucosal T Cells That Produce TGFβ after Lipopolysaccharide Stimulation